Impact of Fluoride Vanish Application in Dental Prevention for Elderly
Phase 4
Completed
- Conditions
- Tooth Decay
- Interventions
- Drug: Duraphat
- Registration Number
- NCT01038817
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Brief Summary
This study questions the interest of fluoride varnish dental application in preventing tooth decay in a population of institutionalised elderly people.
- Detailed Description
Application of fluoride varnish on one side of the mandibles (left or right, randomly selected) in a population of institutionalised elderly people.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 179
Inclusion Criteria
- patient hospitalised in nursing home or long-stay hospital department
- patient older than 18 years old
- obtention of informed consent
- 3 or more healthy or treated teeth on each side (left and right) of the mandibles
Exclusion Criteria
- patient in palliative care or end-of-life care
- patient without social security affiliation
- patient participating in another research dealing with dental care
- contra-indication to fluoride varnish
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description fluoride varnish Duraphat Duraphat: Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)
- Primary Outcome Measures
Name Time Method incidence of tooth decay at endpoint. Comparison, between the treated and not treated side of the mandibles 2 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Duraphat's efficacy in preventing dental caries in elderly populations?
How does fluoride varnish compare to other remineralization agents in managing tooth decay among institutionalized seniors?
Are there specific biomarkers that predict response to Duraphat in geriatric dental prevention strategies?
What adverse events are associated with Duraphat application in elderly patients and how are they managed?
What are the therapeutic alternatives to Duraphat in Phase IV trials for dental caries prevention in the elderly?
Trial Locations
- Locations (1)
APHP, Louis Mourier Hospital
🇫🇷Colombes, France
APHP, Louis Mourier Hospital🇫🇷Colombes, France